US Narcolepsy Market

ID: MRFR/Pharma/16448-HCR 100 Pages Satyendra Maurya Last Updated: September 15, 2026
United States Narcolepsy Market Research Report: Size, Share, Trend Analysis By End Users (Hospitals, Clinics, Home Care Settings) By Treatment Type (Stimulants, Sodium Oxybate, Wakefulness-Promoting Agents, Antidepressants) By Diagnosis Method (Polysomnography, Multiple Sleep Latency Test, Clinical Evaluation) By Types of Narcolepsy (Type 1 Narcolepsy, Type 2 Narcolepsy, Secondary Narcolepsy) - Growth Outlook & Industry Forecast 2025 To 2035
US Narcolepsy Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.88%
2024 Market Size$ 740 Million
2025 Market Size$ 776.11 Million
2035 Market Size$ 1,250 Million
Key Players
Jazz Pharmaceuticals
Teva Pharmaceutical Industries
Eisai Co
Avadel Pharmaceuticals
Purdue Pharma
Novartis
Trends
  • Rising Awareness and Diagnosis
  • Technological Integration in Treatment
  • Evolving Regulatory Landscape
Opportunities
  • Increased Focus on Sleep Disorders
  • Increasing Prevalence of Narcolepsy
  • Growing Support from Advocacy Groups
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Industrial Automation & Equipment, BY Type of Narcolepsy (USD Million)
      1. 4.1.1 Type 1 Narcolepsy
      2. 4.1.2 Type 2 Narcolepsy
      3. 4.1.3 Secondary Narcolepsy
    2. 4.2 Industrial Automation & Equipment, BY Diagnosis Method (USD Million)
      1. 4.2.1 Polysomnography
      2. 4.2.2 Multiple Sleep Latency Test
      3. 4.2.3 Clinical Evaluation
    3. 4.3 Industrial Automation & Equipment, BY Treatment Type (USD Million)
      1. 4.3.1 Stimulants
      2. 4.3.2 Sodium Oxybate
      3. 4.3.3 Wakefulness-Promoting Agents
      4. 4.3.4 Antidepressants
    4. 4.4 Industrial Automation & Equipment, BY End User (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Clinics
      3. 4.4.3 Home Care Settings
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Jazz Pharmaceuticals (IE)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Teva Pharmaceutical Industries (IL)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Eisai Co (JP)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Avadel Pharmaceuticals (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Purdue Pharma (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Novartis (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Otsuka Pharmaceutical (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 UCB (BE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Sage Therapeutics (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE OF NARCOLEPSY
    3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD
    4. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
    5. 6.5 US MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
    9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
    12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE OF NARCOLEPSY, 2024 (% SHARE)
    13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE OF NARCOLEPSY, 2024 TO 2035 (USD Million)
    14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
    16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 (% SHARE)
    17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 (% SHARE)
    19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE OF NARCOLEPSY, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Narcolepsy Market Segmentation

US Narcolepsy Market By Type of Narcolepsy (USD Million, 2025-2035)

  • Type 1 Narcolepsy
  • Type 2 Narcolepsy
  • Secondary Narcolepsy

US Narcolepsy Market By Diagnosis Method (USD Million, 2025-2035)

  • Polysomnography
  • Multiple Sleep Latency Test
  • Clinical Evaluation

US Narcolepsy Market By Treatment Type (USD Million, 2025-2035)

  • Stimulants
  • Sodium Oxybate
  • Wakefulness-Promoting Agents
  • Antidepressants

US Narcolepsy Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Clinics
  • Home Care Settings

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.